전 세계 미만성 폐포 출혈 치료 시장 – 2024년 – 2031년

Global Diffusive Alveolar Hemorrhage Treatment Market - 2024 - 2031

상품코드MD8613
발행기관DataM Intelligence
발행일2024.09.23
페이지 수175 Pages
포맷PDF + EXCEL
커버리지Global

₩6,525,000 – ₩11,775,000

보고서 요약(국문)

보고서 개요
전 세계 미만성 폐포 출혈 치료 시장은 2023년 5억 6,200만 달러에 달했으며, 2024년부터 2031년까지 연평균 6.6%의 성장률을 보이며 2031년에는 9억 2,600만 달러에 이를 것으로 예상됩니다.
미만성 폐포 출혈은 폐의 폐포 공간에서 출혈이 발생하는 생명을 위협하는 질환입니다. 출혈은 세동맥, 세정맥 또는 폐포 중격 모세혈관의 손상이나 염증으로 인해 발생할 수 있습니다. 미만성 폐포 출혈의 증상으로는 호흡곤란, 객혈, 기침 등이 있습니다. 미만성 폐포 출혈(DAH)은 전신 혈관염, 바른 자세 증후군, 전신성 홍반성 루푸스(SLE), 폐 감염, 독성 물질 노출, 응고 장애 및 심장 질환과 같은 질환에 의해 발생합니다.

시장 동향: 성장 요인
미만성 폐포 출혈의 유병률 증가
미만성 폐포 출혈은 드문 질환이기 때문에 유병률에 대한 정확한 기록이 부족합니다. 그러나 여러 자가면역 질환이 이 질환을 유발하는 주요 원인입니다. 그중에서도 전신성 홍반성 루푸스(SLE)와 전신성 혈관염이 DAH의 주요 원인 질환입니다. 이러한 질환들의 발병률이 증가함에 따라 DAH의 발병률 또한 증가할 것으로 예상됩니다. 진단 기술의 발전으로 치료 대상 환자군도 확대되어 시장 성장에 기여하고 있습니다.
예를 들어, 2022년 10월 Annals of Rheumatic Disease 저널에 발표된 세계 역학 연구에 따르면, 전신성 홍반성 루푸스의 연간 발병률은 인구 10만 명당 5.14명입니다. DataM의 추산에 따르면, 이는 2023년 SLE 환자 수가 총 413,530명에 달함을 의미합니다. 문헌 검토 결과, SLE 환자에서 폐포 출혈 발생률은 환자 10만 명당 연간 0.6%에서 5.4% 범위로 나타나며, 이를 통해 2023년 SLE로 인한 미만성 폐포 출혈(DAH) 환자는 총 12,467명으로 추산됩니다.
하지만 이 수치는 전 세계 DAH 환자 수의 일부에 불과합니다. DAH는 감염, 심장 질환, 독소 노출 등 다양한 원인에 의해 발생할 수 있습니다. DAH 발생률이 증가함에 따라 전체 유병률 또한 향후 증가할 것으로 예상되며, 이는 예측 기간 동안 시장 성장의 주요 동력이 될 것입니다.

제약 요인
미만성 폐포 출혈 치료 시장은 질환의 희귀성, 특정 치료 옵션의 부족, 높은 사망률 등 여러 요인으로 인해 제약을 받고 있습니다. 제조업체가 특정 치료법을 개발하려면 임상 시험을 수행하고 혁신적인 치료법의 효능을 검증할 수 있는 충분한 환자 집단이 필요합니다. 환자 집단이 부족하면 제조업체는 혁신에 집중하지 못할 수 있으며, 이는 치료 옵션의 제한과 시장 성장을 저해할 수 있습니다.
시장 세분화 분석
전 세계 미만성 폐포 출혈 치료 시장은 유형, 치료 유형, 환자 유형 및 지역별로 세분화됩니다.

치료 유형 부문에서 약물 치료는 전 세계 미만성 폐포 출혈 치료 시장 점유율의 약 71.3%를 차지했습니다.
미만성 폐포 출혈은 주로 전신성 루푸스, 베게너 육아종증, 굿파스처 증후군 등과 같은 기저 자가면역 질환으로 인해 발생합니다. 미만성 폐포 출혈 치료의 첫 번째 단계는 기저 질환을 치료하는 것입니다. 스테로이드 및 면역억제제와 같은 약물은 이 질환의 주요 치료 옵션으로 남아 있습니다.
프레드니솔론 및 메틸프레드니솔론과 같은 스테로이드는 1차 치료제로 사용됩니다. 또한, 자가면역 파괴를 위해 면역억제제가 처방됩니다. 이러한 면역억제제에는 사이클로포스파미드, 아자티오프린, 메토트렉세이트가 포함됩니다. 지난 10년 동안 면역억제에 효과적인 리툭시맙이 이 목록에 추가되었습니다. 리툭시맙은 ANCA를 생성하는 CD20(+) 형질세포를 억제하는 단클론 항체입니다. 스테로이드와 면역억제제를 병용 투여하면 사망률을 크게 낮출 수 있습니다.
이러한 표준 치료 외에도 출혈을 효과적으로 멈추기 위해 항섬유소용해제, 트롬빈, FVIIa 등 다양한 혈전 형성 촉진 인자를 투여할 수 있지만, 이러한 약물들은 임상적 근거가 매우 부족하여 허가 외 용도로만 처방됩니다.

시장 지역 분석
북미는 2023년 전 세계 미만성 폐포 출혈 치료 시장에서 43.3%의 점유율로 선두를 차지했습니다.
북미가 전 세계 미만성 폐포 출혈 치료 시장을 주도하는 이유는 선진적인 의료 인프라 및 시설, 다양한 치료법에 대한 접근성 용이, 글로벌 제약 업계 선두 기업들이 제공하는 브랜드 의약품의 가용성, 그리고 증가하는 유병률 등 여러 요인 때문입니다.
전신성 루푸스 및 전신성 혈관염과 같은 자가면역 질환은 미만성 폐포 출혈(DAH)의 주요 원인입니다. 이러한 질환의 유병률이 증가함에 따라 북미 지역에서 DAH 발생률도 증가할 것으로 예상됩니다. 예를 들어, 미국 질병통제예방센터(CDC)에 따르면 미국에는 약 20만 4천 명의 전신성 홍반성 루푸스(SLE) 환자가 있는 것으로 추산됩니다. 문헌 검토에 따르면 SLE 환자 중 폐포 출혈 발생률은 1%에서 5.4%에 이르며, DataM의 추산에 따르면 이는 약 6,150건(1,285~11,016건)에 해당합니다.
비록 이 질환은 매우 드물지만, 북미 지역의 선진 의료 시설과 진단 센터는 환자를 적극적으로 진단하고 치료율을 높이고 있습니다. 여기에 로슈, 암젠, 화이자 등 주요 제약 회사에서 제공하는 리툭시맙, 사이클로포스파미드와 같은 표준 치료제의 공급이 더해져 치료를 받는 환자의 수가 전반적으로 증가하고 있습니다.
따라서 이러한 요인들과 역학 데이터, 시장 선도 기업의 매출액을 고려할 때 북미는 세계 시장에서 지배적인 지역으로 꼽힙니다.

시장 세분화
유형별
자가면역성 폐포 출혈
약물 유발성 폐포 출혈
감염 유발성 폐포 출혈
기타
치료 유형별
약물 요법
스테로이드
면역억제제
사이클로포스파미드
리툭시맙
아자티오프린
기타
기타
혈장 교환 요법
대증 치료
환자 유형별
소아
성인
노인
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽
남미
브라질
아르헨티나
기타 남미
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
주요 업체 폐포 출혈 치료제 시장에는 F. Hoffmann-La Roche Ltd, Cadila Pharmaceuticals, Teva Pharmaceuticals USA, Inc., Amgen Inc., Baxter, Pfizer Inc., GSK plc, Horizon Therapeutics plc, Sandoz AG, Sun Pharmaceutical Industries Ltd. 등이 포함됩니다.
보고서 ​​구매 이유:
유형, 치료 유형, 환자 유형 및 지역별 글로벌 폐포 출혈 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.
트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.
모든 세그먼트를 포함한 폐포 출혈 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
모든 주요 기업의 핵심 제품을 포함하는 제품 맵핑 Excel 파일을 제공합니다.

보고서 구매 이유:
글로벌 미만성 폐포 출혈 치료 시장 보고서는 약 62개의 표, 53개의 그림, 그리고 175페이지 분량으로 구성될 예정입니다.
대상 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자 은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Diffusive Alveolar Hemorrhage Treatment Market reached US$ 562 million in 2023 and is expected to reach US$ 926 million by 2031, growing at a CAGR of 6.6% during the forecast period 2024-2031. 
Diffusive alveolar hemorrhage is a life-threatening condition in which bleeding happens in the alveolar spaces of the lung. The bleeding can be caused by injury or inflammation in the arterioles venules, or alveolar septal capillaries. The symptoms of diffusive alveolar hemorrhage are dyspnea, hemoptysis, cough, etc. Diffusive alveolar hemorrhage (DAH) is caused by conditions such as systemic vasculitis, good posture syndrome, systemic lupus erythematosus (SLE), pulmonary infections, toxic compound exposures, coagulation disorders, and cardiac disorders.
Market Dynamics: Drivers
Rising prevalence of diffusive alveolar hemorrhage
The prevalence of diffusive alveolar hemorrhage is not well documented, due to the rarity of the condition. However, several autoimmune conditions majorly precipitate the condition. Among these, systemic lupus erythematosus (SLE), and systemic vasculitis are the major autoimmune conditions behind DAH. As their incidence rises, the incidence of DAH is also anticipated to rise. With the advancements in diagnostics, the target population for treatment also rises, contributing to the overall market growth.
For instance, according to a global epidemiology study published in the Annals of Rheumatic Disease journal in October 2022, the annual incidence of systemic lupus erythematosus is 5.14 per 100,000 person-years. As per DataM estimates, this reflects a total of 413,530 cases of SLE in 2023. Upon literature review, the incidence of alveolar hemorrhage among SLE patients ranges from 0.6% to 5.4% per 100,000 patient-years, which makes the total incidence of 12,467 diffusive alveolar hemorrhage patients in 2023, caused by SLE.
However, this number only makes up a specific portion of total DAH patients worldwide. The condition can be caused by various conditions such as infections, cardiac disorders, toxin exposures, etc. As the incidence rises, the total prevalence of DAH is also anticipated to rise in the future, which is the major growth driving factor for the market in the forecast period.
Restraints
The market for diffusive alveolar hemorrhage treatment is restrained by several factors such as limited patient population i.e., rarity of the condition, lack of specific treatment options, and high mortality rate. For the manufacturers to develop a specific treatment option, there should be an appropriate number of patient population to conduct clinical trials and validate the efficacy of their innovative treatment. Due to lack of sufficient patient population, the manufacturers may not focus on innovations, which may limit the treatment options and restrain the market growth.
Market Segment Analysis
The global diffusive alveolar hemorrhage treatment market is segmented based on type, treatment type, patient type, and region.
Pharmacotherapy in the treatment type segment accounted for approximately 71.3% of the global diffusive alveolar hemorrhage treatment  market share
Diffusive alveolar hemorrhage is majorly caused by underlying autoimmune conditions such as systemic lupus erythematosus, Wegener's granulomatosis, Goodpasture syndrome, etc. To treat DAH, it is the primary step to treat the underlying conditions. Drugs such as steroids and immunosuppressants remain the mainstay therapeutic options for this condition.
Steroids such as prednisolone, and methylprednisolone remain the first-line therapeutic agents. In addition, immunosuppressant drugs are prescribed for autoimmune destruction. These immunosuppressants include cyclophosphamide, azathioprine, methotrexate. In the past decade, Rituximab was added to this list, which is effective for immunosuppression. Rituximab is a monoclonal antibody which acts by suppressing ANCA-producing CD20(+) plasma cells. By the combination prescription of Steroids and immunosuppressants, the mortality rate can be hugely reduced. 
In addition to these standard treatments, to effectively stop bleeding, various prothrombotic factors including antifibrinolytics, thrombin, and FVIIa can be given, but these agents have very little clinical evidence and are only prescribed for off-label use. 
Market Geographical Analysis 
North America dominates the global diffusive alveolar hemorrhage treatment market with a share of 43.3% in 2023
North America dominates the global diffusive alveolar hemorrhage treatment market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, and increasing prevalence, etc.
Autoimmune conditions such as systemic lupus erythematosus, and systemic vasculitis are the main culprits behind diffusive alveolar hemorrhage (DAH). As their prevalence is rising, the incidence of DAH is anticipated to rise in the region. For instance, according to Centers for Disease Control and Prevention (CDC), estimated there are 204,000 patients with SLE in the U.S. According to the literature review, among SLE patients, alveolar hemorrhage incidence ranges from 1% to 5.4% of lupus patients, which accounts for approximately 6150 (1,285-11,016) cases as per DataM estimates.
Although the condition is very rare, the region’s advanced healthcare facilities and diagnostic centers actively diagnose the patient and improve the treatment rate. This combined with the availability of gold-standard drugs such as rituximab, and cyclophosphamide offered by leading pharmaceutical companies like Roche, Amgen, Pfizer, etc. improve the overall number of patients receiving the treatment.
Hence, considering these factors, along with the epidemiological data and sales figures by market leaders, North America is designated as a dominant region in the global market.
Market Segmentation
By Type
Autoimmune Induced Alveolar Hemorrhage
Drug-Induced Alveolar Hemorrhage
Infection Induced Alveolar Hemorrhage
Others
By Treatment Type
Pharmacotherapy
Steroids
Immunosuppressants
Cyclophosphamide
Rituximab
Azathioprine
Others
Others
Plasma Exchange Therapy
Supportive Care
By Patient Type
Pediatrics
Adults
Geriatrics
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major players in the diffusive alveolar hemorrhage treatment market include F. Hoffmann-La Roche Ltd, Cadila Pharmaceuticals., Teva Pharmaceuticals USA, Inc., Amgen Inc., Baxter., Pfizer Inc., GSK plc, Horizon Therapeutics plc, Sandoz AG, and Sun Pharmaceutical Industries Ltd. among others.
Why Purchase the Report?
To visualize the global diffusive alveolar hemorrhage treatment market segmentation based on type, treatment type, patient type, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of diffusive alveolar hemorrhage treatment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global diffusive alveolar hemorrhage treatment market report would provide approximately 62 tables, 53 figures, and 175 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment Type
3.3. Snippet by Patient Type
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of diffusive alveolar hemorrhage
4.1.1.2. Advancements in diagnostics and increasing treatment rate
4.1.2. Restraints
4.1.2.1. Lack of specific treatment options
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Unmet Needs
5.5. PESTEL Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Autoimmune Induced Alveolar Hemorrhage*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Drug-Induced Alveolar Hemorrhage
6.4. Infection Induced Alveolar Hemorrhage
6.5. Others
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Pharmacotherapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Steroids
7.4. Immunosuppressants
7.4.1. Cyclophosphamide
7.4.2. Rituximab
7.4.3. Azathioprine
7.4.4. Others
7.5. Plasma Exchange Therapy
7.6. Supportive Care
8. By Patient Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
8.1.2. Market Attractiveness Index, By Patient Type
8.2. Pediatrics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
8.4. Geriatrics
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.3.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.2. Germany
9.3.5.3. UK
9.3.5.4. France
9.3.5.5. Italy
9.3.5.6. Spain
9.3.5.7. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.4.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.2. Brazil
9.4.5.3. Argentina
9.4.5.4. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.5.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.2. China
9.5.5.3. India
9.5.5.4. Japan
9.5.5.5. South Korea
9.5.5.6. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. F. Hoffmann-La Roche Ltd.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Cadila Pharmaceuticals.
11.3. Teva Pharmaceuticals USA, Inc.
11.4. Amgen Inc.
11.5. Baxter.
11.6. Pfizer Inc.
11.7. GSK plc
11.8. Horizon Therapeutics plc
11.9. Sandoz AG
11.10. Sun Pharmaceutical Industries Ltd. (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

F. Hoffmann-La Roche Ltd., 4. Key Developments, Cadila Pharmaceuticals., Teva Pharmaceuticals USA, Inc., Amgen Inc., Baxter., Pfizer Inc., GSK plc, Horizon Therapeutics plc, Sandoz AG

표 목록 (Tables)

List of Tables

Table 1 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 9 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2022-2031 (US$ Million)

Table 11 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Diffusive Alveolar Hemorrhage Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 15 North America Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2022-2031 (US$ Million)

Table 16 North America Diffusive Alveolar Hemorrhage Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 18 South America Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 19 South America Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2022-2031 (US$ Million)

Table 20 South America Diffusive Alveolar Hemorrhage Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 23 Europe Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2022-2031 (US$ Million)

Table 24 Europe Diffusive Alveolar Hemorrhage Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Value, By Patient Type, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 33 F. Hoffmann-La Roche Ltd: Overview

Table 34 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 35 F. Hoffmann-La Roche Ltd: Key Developments

Table 36 Cadila Pharmaceuticals.: Overview

Table 37 Cadila Pharmaceuticals.: Product Portfolio

Table 38 Cadila Pharmaceuticals.: Key Developments

Table 39 Teva Pharmaceuticals USA, Inc.: Overview

Table 40 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 41 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 42 Amgen Inc.: Overview

Table 43 Amgen Inc.: Product Portfolio

Table 44 Amgen Inc.: Key Developments

Table 45 Baxter.: Overview

Table 46 Baxter.: Product Portfolio

Table 47 Baxter.: Key Developments

Table 48 Pfizer Inc.: Overview

Table 49 Pfizer Inc.: Product Portfolio

Table 50 Pfizer Inc.: Key Developments

Table 51 GSK plc: Overview

Table 52 GSK plc: Product Portfolio

Table 53 GSK plc: Key Developments

Table 54 Horizon Therapeutics plc: Overview

Table 55 Horizon Therapeutics plc: Product Portfolio

Table 56 Horizon Therapeutics plc: Key Developments

Table 57 Sandoz AG: Overview

Table 58 Sandoz AG: Product Portfolio

Table 59 Sandoz AG: Key Developments

Table 60 Sun Pharmaceutical Industries Ltd.: Overview

Table 61 Sun Pharmaceutical Industries Ltd.: Product Portfolio

Table 62 Sun Pharmaceutical Industries Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Diffusive Alveolar Hemorrhage Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 3 Global Diffusive Alveolar Hemorrhage Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 4 Global Diffusive Alveolar Hemorrhage Treatment Market Share, By Patient Type, 2023 & 2031 (%)

Figure 5 Global Diffusive Alveolar Hemorrhage Treatment Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Diffusive Alveolar Hemorrhage Treatment Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 Autoimmune Induced Alveolar Hemorrhage Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Drug-Induced Alveolar Hemorrhage Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 9 Infection Induced Alveolar Hemorrhage Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 10 Others Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 11 Global Diffusive Alveolar Hemorrhage Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2031 (%)

Figure 12 Pharmacotherapy Treatment Type in Global Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 13 Plasma Exchange Therapy Treatment Type in Global Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Supportive Care Treatment Type in Global Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 15 Global Diffusive Alveolar Hemorrhage Treatment Market Y-o-Y Growth, By Patient Type, 2023-2031 (%)

Figure 16 Pediatrics Patient Type in Global Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Adults Patient Type in Global Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 18 Geriatrics Patient Type in Global Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 19 Global Diffusive Alveolar Hemorrhage Treatment Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 20 North America Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 21 North America Diffusive Alveolar Hemorrhage Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 22 North America Diffusive Alveolar Hemorrhage Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 23 North America Diffusive Alveolar Hemorrhage Treatment Market Share, By Patient Type, 2023 & 2031 (%)

Figure 24 North America Diffusive Alveolar Hemorrhage Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 25 South America Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 26 South America Diffusive Alveolar Hemorrhage Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 27 South America Diffusive Alveolar Hemorrhage Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 28 South America Diffusive Alveolar Hemorrhage Treatment Market Share, By Patient Type, 2023 & 2031 (%)

Figure 29 South America Diffusive Alveolar Hemorrhage Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 30 Europe Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 31 Europe Diffusive Alveolar Hemorrhage Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 32 Europe Diffusive Alveolar Hemorrhage Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 33 Europe Diffusive Alveolar Hemorrhage Treatment Market Share, By Patient Type, 2023 & 2031 (%)

Figure 34 Europe Diffusive Alveolar Hemorrhage Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 35 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 36 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 37 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 38 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Share, By Patient Type, 2023 & 2031 (%)

Figure 39 Asia-Pacific Diffusive Alveolar Hemorrhage Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 40 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Value, 2022-2031 (US$ Million)

Figure 41 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 42 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 43 Middle East and Africa Diffusive Alveolar Hemorrhage Treatment Market Share, By Patient Type, 2023 & 2031 (%)

Figure 44 F. Hoffmann-La Roche Ltd: Financials

Figure 45 Cadila Pharmaceuticals.: Financials

Figure 46 Teva Pharmaceuticals USA, Inc.: Financials

Figure 47 Amgen Inc.: Financials

Figure 48 Baxter.: Financials

Figure 49 Pfizer Inc.: Financials

Figure 50 GSK plc: Financials

Figure 51 Horizon Therapeutics plc: Financials

Figure 52 Sandoz AG: Financials

Figure 53 Sun Pharmaceutical Industries Ltd.: Financials